April 2014
Volume 55, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2014
The Sympatholytic Non-selective β-blocker PROPRANOLOL as A Non-invasive Therapeutic Approach for the Treatment of Chronic Central Serous Chorioretinopathy (CSC)
Author Affiliations & Notes
  • Jose A Cardillo
    Retina, Ribeirão Preto Medical School-University of São Paulo, Ribeirão Preto, Brazil
  • Murilo Wendeborn Rodrigues
    Retina, Ribeirão Preto Medical School-University of São Paulo, Ribeirão Preto, Brazil
  • Leticia Fernandes Barroso
    Retina, Ribeirão Preto Medical School-University of São Paulo, Ribeirão Preto, Brazil
  • Rubens C Siqueira
    Retina, Ribeirão Preto Medical School-University of São Paulo, Ribeirão Preto, Brazil
  • Rodrigo Jorge
    Retina, Ribeirão Preto Medical School-University of São Paulo, Ribeirão Preto, Brazil
  • Footnotes
    Commercial Relationships Jose Cardillo, None; Murilo Rodrigues, None; Leticia Barroso, None; Rubens Siqueira, None; Rodrigo Jorge, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 6380. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Jose A Cardillo, Murilo Wendeborn Rodrigues, Leticia Fernandes Barroso, Rubens C Siqueira, Rodrigo Jorge; The Sympatholytic Non-selective β-blocker PROPRANOLOL as A Non-invasive Therapeutic Approach for the Treatment of Chronic Central Serous Chorioretinopathy (CSC). Invest. Ophthalmol. Vis. Sci. 2014;55(13):6380.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: To evaluate the effect of systemically administered β-blocker propranolol on the course of central serous chorioretinopathy. Our goal is to research potential alternative tool for chronic CSC as monotherapy or as adjunct to more invasive laser techniques

Methods: Fourteen CSC-patients with a documented-persistent leakage of at least 4 months were treated by oral propranolol 20 mg twice a day and followed up at monthly intervals for 6 months. Best-corrected visual acuity (BCVA), fluorescein angiography (FA), indocyanine green angiography (ICGA), central macular thickness (CMT) quantified by ocular coherence tomography (OCT), were recorded at baseline and follow-up visits

Results: At 3 months, BCVA was significantly enhanced in the treatment group (P =.006) compared with baseline. An improvement in central macular thickness and leakage on fluorescein angiography was noted in all treated patients starting as early as 30 days following treatment

Conclusions: β-blocker has a plausible mechanism of action in CSC and may characterize a potential alternative to the present standard of care meriting further evaluation.

Keywords: 726 stress response • 666 pump/barrier function • 503 drug toxicity/drug effects  
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×